Study: NCT05298254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted HSV formulation 1
Description: Two doses of the non-adjuvanted HSV formulation 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted HSV formulation 2
Description: Two doses of the non-adjuvanted HSV formulation 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted HSV formulation 3
Description: Two doses of the non-adjuvanted HSV formulation 3 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV formulation 1 with adjuvant 1
Description: Two doses of the HSV formulation 1 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV formulation 2 with adjuvant 1
Description: Two doses of the HSV formulation 2 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV formulation 3 with adjuvant 1
Description: Two doses of the HSV formulation 3 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV formulation 1 with adjuvant 2
Description: Two doses of the HSV formulation 1 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV formulation 2 with adjuvant 2
Description: Two doses of the HSV formulation 2 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV formulation 3 with adjuvant 2
Description: Two doses of the HSV formulation 3 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of Placebo administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I and Part II of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of Placebo administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I and Part II of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSVTI_F1
Description: Two doses of the formulation of the HSVTI_F1 selected from Part I of the study administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part II of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSVTI_F2
Description: Two doses of the formulation of the HSVTI_F2 selected from Part I of the study administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part II of the study.